

## An Industry Perspective on Managing Specific Elements in Public Standards

**Presented By**: Philip Travis Associate Director Compendial Compliance and Advocacy

**4th PQRI El Workshop** 09 November 2020






### **Discussion Outline**

- 1. Evolution
- 2. Development
- 3. Opportunities
- 4. Challenges












Public

- Serving the patients
- Safe and effective medicine provided through a reliable and efficient system
- Foundation of working together and understanding our impact on the common goal of serving the patient



#### 1. Today relative to past – Global Industry

- Increased processes
- Increased dosage forms
- Increased complexity (Biotherapeutics)
- Increased Specificity (Methods)
- Increased Accuracy (Methods and acceptance criteria)
- Material/Product quality profile becomes more of a manufacturing fingerprint

#### 2. Future

ublic

- New innovations (Medicine, Drug Delivery, Manufacturing, Analysis)
- Improve time between establishing safe/effective medicine and patient access





- 1. Today relative to past Global Regulatory and Pharmacopoeia
  - Increased standard sources (#Active Organizations)
  - Increased activities (Rate of change)
  - Increase challenge to establish a single fixed standard
  - Increased complexity of standards
    - Methods; Theory; Equipment Qualification; Etc.
  - Increased complexity of standard application
    - Alternative methods; Method verification; Regulatory variations

#### 2. Future

 Increased communication, collaboration/harmonization and flexibility










#### ICH Knowledge and Safety Based Guidelines

- 1. Global Regulatory, Pharmacopeia, and Industry collaboration and harmonization
- 2. Focuses resources where risk is identified
- 3. Safety based limits reduce conflicts across multiple individual applications
- 4. Flexible methodology reduce conflicts across multiple individual applications
- 5. Simplify Pharmacopeial content, resources and supports further harmonization efforts
- 6. Supports innovation through flexibility








## Development







## Development




MERCK



### 2015-2018: ICH Q3D Learning Curve

- 1. Theory becomes Application
  - Industry risk assessments and control strategy confirmation
  - Regulatory compliance confirmation and change control
- 2. Managing the learning curve and secondary impact across market portfolio
  - Deleting Heavy Metals
  - Retaining specified elements





# **Opportunities**








### **Opportunities**

- 1. Simplify ongoing alignment with ICH Q3D
  - Direct reference to ICH Q3D content (Ex. Ph. Eur. 5.20 Elemental Impurities)
    - Define revision implementation timelines
    - Minor revisions Suggest 6 months
    - Major revisions To be determined base on unique attributes
- 2. Maximize benefits of Knowledge and Safety based expectations
  - Simplify monograph and chapter content (Ex. ICH Q3C Residual Solvent applications)
  - Define a universal standard where retaining an element is justified
  - Where justified, retained elements should not be limited to a single method and limits should refer to Q3D safety expectations
- 3. Additional Pharmacopeial implementation
  - Concurrent Heavy Metals and specific element transition
  - Retain element specific general chapters as resource
  - Share knowledge with Regulatory and Pharmacopeial Agencies internationally as they adopt ICH Q3D





# Challenges







### Challenges

- 1. Define a universal standard where retaining an element is justified
  - "Other Element" limit in a material monograph is not a product Permitted Daily Exposure limit
- 2. Avoid conflicts with ICH Q3D
  - Reinterpretation
  - Retaining or adding rigid requirements (methods/limits)
- 3. Managing changes and the compounded impact to multi-national filings
  - Ex. Change specified element
    - Assess Product(s) control strategy
    - Method development increases implementation time
    - Where risk is identified, update control strategy
    - (These are not the only compendial changes occurring)



#
Pharmacopoeias



# element sources with public standards



Individual Pharmacopeia change schedule







## Thank You

